Trials / Terminated
TerminatedNCT03590730
Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (actual)
- Sponsor
- Keimyung University Dongsan Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The prevalence of valvular heart disease is on the rise along with the aging society and the generalization of echocardiography. Furthermore, the rheumatic valvular heart disease is much more prevalent in Asia than in Western countries, and the frequency of valve disease is higher in Asia. The effect of an implantable cardioverter defibrillator (ICD) in the primary prevention of sudden cardiac death in ischemic cardiomyopathy is well established and has become a standard of care. However, there is limited research on the effect of ICD implantation for primary prevention in patients with heart failure due to valvular heart disease. In a small study, the incidence of fatal cardiac arrhythmia was lower in patients with valvular cardiomyopathy (5%) who received ICD implantation for primary prevention than in those with ischemic cardiomyopathy. But there is also a report that the appropriate ICD treatment is not different from that of ischemic heart disease in valvular heart disease patients. Therefore, it is necessary to study the primary prevention effect of ICD on valvular cardiomyopathy in a larger number of patients. The purpose of this study was to investigate the effect of ICD on the prevention of sudden cardiac death in patients with heart failure due to valvular heart disease through prospective, multicenter, and observational studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ICD implantation | ICD will be implanted according to current guidelines recommendations. |
Timeline
- Start date
- 2017-11-15
- Primary completion
- 2019-07-10
- Completion
- 2021-07-15
- First posted
- 2018-07-18
- Last updated
- 2023-10-19
Locations
12 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03590730. Inclusion in this directory is not an endorsement.